Proteus Digital Health and Otsuka Pharmaceutical have expanded their partnership on digital therapeutics.
On Thursday, Proteus announced that it received $88 million from the pharma company, which will go toward the continued development and commercialization of its ingestible sensor pill platform. Additionally, the five-year deal will also support the investigation of a wider digital medicine...
As digital therapeutics move to cross boundaries of regulatory approval and efficacy data, the healthcare industry will begin to move to a bifurcated world of digital health apps in the same way that drugs are now divided up into largely unregulated supplements and heavily regulated pharmaceuticals.
At the Digital Health Innovation Summit last week in Boston, Sanofi Ventures Senior Director of...
Digital therapeutics maker Akili Interactive Labs today announced a deal with the University of California’s governing board concerning exclusive licensing of a new technology that will combine the company’s focus on neural systems with physical activity.
Developed at the Neuroscape Lab at UCSF, the tech follows in the footsteps of Akili’s other efforts in that it is primarily delivered through a...
Photo credit: RX.Health/Mt. Sinai
Rx.Health — a Mount Sinai Health System spinoff that has built an app prescription platform for enterprises — has raised $1.8 million in seed funding. According to a statement, the investment will help the company pursue new clients and support the launch of its digital therapeutics and patient engagement tool, Bulk Prescription.
"We've seen a tremendous increase in the demand for our services...
Dthera Sciences, a San Diego-based developer of clinical and consumer digital therapeutics for individuals with neurodegenerative conditions, announced today that its development stage intervention, DTHR-ALZ, has been granted Breakthrough Device designation by the FDA.
As laid out in the 21st Century Cures Act, the Breakthrough Devices Program looks to streamline new medical technologies that...
A recent small study published in Nature’s Translational Psychiatry journal observed a change in the brain networking and behavior of boys receiving a video game-based treatment for ADHD.
Conducted in Singapore, the study was conducted as part of a larger controlled investigation of boys with ADHD. It compared an intervention group of 18 participants (mean age 9 years) to a control arm of 11...
Boston-based digital therapeutics company Akili Interactive Labs announced this morning that it has added an extra $13 million to its previously announced Series C financing. Together, this brings the company’s 2018 funding to $68 million, and its total backing to just over $140 million.
The additional investment from CLSA, Omidyar Technology Ventures, Digital Garage Group, and Fearless Ventures...
Digital chronic disease management company Omada Health announced today the launch of new programs designed to support individuals with Type 2 diabetes and hypertension.
Accompanying these are a set of new features for the enterprise and health plan platform focused on medication adherence and remote monitoring, all of which comprise what a representative from the company described as “the...
The past month has seen a succession of publications offering support for Click Therapeutics’ digital offering for patients with major depressive disorder (MDD).
The studies, published in npj Digital Medicine, the Journal of Affective Disorders, and presented at the Society of Biological Psychiatry Annual Scientific Convention in New York, showed the therapeutic to reduce symptoms, pair well with...
Digital technologies are cementing their place across healthcare, and the pharmaceutical sector is no exception.
This week Boston was host to the Biotechnology Innovation Organization’s annual conference, a multi-day gathering of leading pharma and biotech leaders from across the globe. While, admittedly, digital health wasn’t always the primary interest of many attendees and speakers, it was...
